Tandem Diabetes Care (TNDM) Shares Gap Down to $2.35
Tandem Diabetes Care Inc (NASDAQ:TNDM)’s share price gapped down before the market opened on Monday . The stock had previously closed at $2.55, but opened at $2.35. Tandem Diabetes Care shares last traded at $2.35, with a volume of 6296400 shares changing hands.
Several research firms have recently commented on TNDM. Robert W. Baird restated a “hold” rating and set a $3.00 price target on shares of Tandem Diabetes Care in a report on Sunday, November 19th. Zacks Investment Research cut shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a report on Saturday, January 20th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $11.29.
The company has a debt-to-equity ratio of -2.70, a quick ratio of 0.88 and a current ratio of 1.90. The stock has a market cap of $23.78, a price-to-earnings ratio of -0.12 and a beta of 0.44.
COPYRIGHT VIOLATION WARNING: “Tandem Diabetes Care (TNDM) Shares Gap Down to $2.35” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://theolympiareport.com/2018/02/12/tandem-diabetes-care-tndm-shares-gap-down-to-2-35.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.